Clearstead Advisors’s Bionano Genomics BNGO Stock Holding History

Clearstead Advisors’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$730	–	1372
2022 Q4	$730	Buy	+1	New	+$1.26K	﹤0.01%	1198

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Clearstead Advisors's BNGO Position: Q1 2023 in Review

Clearstead Advisors sold out of Bionano Genomics (BNGO) in Q1 2023, closing a stake of 1 share — an estimated $730 sold.

Clearstead Advisors first reported a position in BNGO in Q4 2022 and held it in 1 quarter. The position peaked at $730 in Q4 2022. 126 funds tracked by Wall St. Rank hold BNGO as of Q1 2023.

Clearstead Advisors reported no remaining Bionano Genomics position as of Q1 2023 after selling out during the quarter.
Clearstead Advisors sold 1 Bionano Genomics share in Q1 2023, an estimated $730.
Clearstead Advisors first reported a position in Bionano Genomics in Q4 2022 and held it in 1 quarter.
Clearstead Advisors's Bionano Genomics position peaked at $730 in Q4 2022.
126 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2023.

Based on Clearstead Advisors's 13F filing for Q1 2023, filed 9 May 2023.